Image credit: Canva.
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow. Although a blood stem cell transplant from a healthy donor can help, sometimes relapse of the disease may occur. A clinical trial led by Nirali N. Shah, M.D., M.H.Sc., Lasker Clinical Research Scholar in the Pediatric Oncology Branch, is researching a stem cell therapy to reduce potential relapse for AML. The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, please contact the NCI Pediatric Leukemia Lymphoma TCT Team at (240) 760-6970 or NCILLTCT@nih.gov
Clinicaltrials.gov identifier: NCT04849910
NCI Protocol ID: NCI000731
Official Title: A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients With Acute Myeloid Leukemia Who Are at High-Risk for Leukemia Relapse Following Hematopoietic Cell Transplantation
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.
